Read More

Lyra Therapeutics Reports Topline Results From Phase 3 ENLIGHTEN 1 Trial For LYR-210 in Chronic Rhinosinusitis; ENLIGHTEN 1 Trial Did Not Meet Its Primary Endpoint; Company Plans To Evaluate Full Dataset And Path Forward

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forwardWATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the

LYRA

Read More

GM-Backed Self-Driving Company Momenta Readies For US IPO Launch: Report

Auto giant General Motors-backed Beijing Momenta Technology Co., a Chinese self-driving firm, has quietly filed for a potential IPO in the U.S., report says. Momenta reportedly aims to raise $200-$300 million through share sales, with discussions ongoing. The move underscores Momenta's rapid growth and signifies a significant step in its global expansion strategy.

GM

Read More

Genomics firm Twist Bioscience’s Momentum To Continue Throughout 2024, Analyst Says

Twist Bioscience reports strong Q2 earnings, with sales up 25% YoY to $75.3M and orders increasing by 45%. Gross margin expands to 41%. Fiscal year guidance was raised, and William Blair sees continued growth momentum. Analysts reaffirm Outperform ratings.

TWST